Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-27
Closed -$2.04K 1106
2026
Q1
$2.04K Hold
27
﹤0.01% 755
2025
Q4
$2.01K Buy
+27
New +$1.97K ﹤0.01% 717
2025
Q2
Sell
-53
Closed -$3.27K 842
2025
Q1
$3.27K Buy
53
+27
+104% +$1.79K ﹤0.01% 695
2024
Q4
$1.87K Sell
26
-809
-97% -$63.2K ﹤0.01% 743
2024
Q3
$68K Buy
835
+96
+13% +$7.68K 0.02% 334
2024
Q2
$54.9K Sell
739
-339
-31% -$25.4K 0.02% 348
2024
Q1
$84K Buy
1,078
+291
+37% +$21.6K 0.03% 332
2023
Q4
$56.2K Sell
787
-977
-55% -$68K 0.02% 410
2023
Q3
$122K Sell
1,764
-50
-3% -$3.78K 0.04% 299
2023
Q2
$147K Buy
1,814
+1,142
+170% +$93.3K 0.04% 289
2023
Q1
$54.2K Buy
672
+12
+2% +$966 0.02% 468
2022
Q4
$49K Buy
+660
New +$47K 0.01% 483

Other funds holding HOLX

Park Place Capital's HOLX Position: Q2 2026 in Review

Park Place Capital sold out of Hologic (HOLX) in Q2 2026, closing a stake of 27 shares — an estimated $2.04K sold.

Park Place Capital first reported a position in HOLX in Q4 2022 and held it in 12 quarters. The position peaked at $147K in Q2 2023. 3 funds tracked by Wall St. Rank hold HOLX as of Q2 2026.

  • Park Place Capital reported no remaining Hologic position as of Q2 2026 after selling out during the quarter.
  • Park Place Capital sold 27 Hologic shares in Q2 2026, an estimated $2.04K.
  • Park Place Capital first reported a position in Hologic in Q4 2022 and held it in 12 quarters.
  • Park Place Capital's Hologic position peaked at $147K in Q2 2023.
  • 3 funds tracked by Wall St. Rank held Hologic as of Q2 2026.

Based on Park Place Capital's 13F filing for Q2 2026, filed 14 Aug 2026.